Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial

Background & AimsGenetic variation in both patatin-like phospholipase domain-containing protein-3 (PNPLA3) (I148M) and the transmembrane 6 superfamily member 2 protein (TM6SF2) (E167K) influences severity of liver disease, and serum triglyceride concentrations in non-alcoholic fatty liver disease (NAFLD), but whether either genotype influences the responses to treatments is uncertain.MethodsOne hundred three patients with NAFLD were randomised to omega-3 fatty acids (DHA+EPA) or placebo for 15–18 months in a double blind placebo controlled trial. Erythrocyte enrichment with DHA and EPA was measured by gas chromatography. PNPLA3 and TM6SF2 genotypes were measured by PCR technologies. Multivariable linear regression and analysis of covariance were undertaken to test the effect of genotypes on omega-3 fatty acid enrichment, end of study liver fat percentage and serum triglyceride concentrations. All models were adjusted for baseline measurements of each respective outcome.ResultsFifty-five men and 40 women (Genotypes PNPLA3 I148M, 148I/I = 41, 148I/M = 43, 148M/M = 11; TM6SF2 E167K 167E/E = 78, 167E/K+167K/K = 17 participants) (mean ± SD age, 51 ± 11 years) completed the trial. Adjusting for baseline measurement, measured covariates and confounders, PNPLA3 148M/M variant was independently associated with percentage of DHA enrichment (B coefficient −1.02 (95% CI −1.97, −0.07), p = 0.036) but not percentage of EPA enrichment (B coefficient −0.31 (95% CI −1.38, 0.75), p = 0.56). This genotype was also independently associated with end of study liver fat percentage (B coefficient 9.5 (95% CI 2.53, 16.39), p = 0.008), but not end of study triglyceride concentration (B coefficient −0.11 (95% CI −0.64, 0.42), p = 0.68).ConclusionsPNPLA3 148M/M variant influences the changes in liver fat and DHA tissue enrichment during the trial but not the change in serum triglyceride concentration.